Valuation: Alvotech

Market Cap 1.36B 1.18B 1.1B 1B 1.89B 129B 1.92B 12.9B 5.05B 64.75B 5.09B 4.98B 216B P/E 2026 *
14.3x
P/E 2027 * 8.29x
Enterprise Value 2.44B 2.11B 1.98B 1.81B 3.4B 233B 3.46B 23.21B 9.09B 116B 9.16B 8.96B 389B EV / Sales 2026 *
3.72x
EV / Sales 2027 * 3.06x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.05%
1 week-1.82%
Current month-8.50%
1 month+14.94%
3 months+5.01%
6 months-22.27%
Current year-26.51%
1 week 3.68
Extreme 3.685
3.88
1 month 3.04
Extreme 3.04
4.12
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.25
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
26/2/26 Buy

Founder

2,701,617 0.9038%
26/2/26
Aztiq Pharma Partners SARL
BuyCompany 2,701,617 0.9038%
15/2/26 Sell

Founder

2,701,617 0.9038%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-1.82%-55.75%-57.64% 1.36B
-1.56%+0.75%+3.59%+14.45% 49.54B
-0.69%+6.25%+492.36%+585.40% 44.06B
+0.08%+11.23%+23.99%+81.74% 40.85B
+0.76%+6.85%+35.40%+10.92% 40.14B
+4.73%+13.29%+27.76%+54.22% 34.17B
+0.51%+5.29%+34.62%+126.87% 16.9B
-0.41%+4.08% - - 16.78B
-0.34%-0.03%+4.31%+20.81% 14B
+1.81%+20.45%+89.35%+31.49% 13.46B
Average +0.38%+6.79%+72.85%+96.47% 27.13B
Weighted average by Cap. +0.39%+7.35%+106.07%+137.22%

Financials

2026 *2027 *
Net sales 656M 569M 532M 486M 914M 62.6B 930M 6.24B 2.45B 31.33B 2.46B 2.41B 105B 793M 687M 643M 587M 1.1B 75.59B 1.12B 7.54B 2.95B 37.83B 2.98B 2.91B 126B
Net income 91.8M 79.55M 74.47M 67.95M 128M 8.76B 130M 873M 342M 4.38B 345M 337M 14.62B 151M 131M 123M 112M 211M 14.44B 214M 1.44B 564M 7.23B 568M 556M 24.11B
Net Debt 1.08B 939M 879M 802M 1.51B 103B 1.53B 10.31B 4.04B 51.72B 4.07B 3.98B 173B 1.07B 923M 864M 789M 1.48B 102B 1.51B 10.13B 3.97B 50.86B 4B 3.91B 170B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
11/08/26 US$3.800 +0.80% 772,808
10/08/26 US$3.770 -1.05% 1,022,803
07/08/26 US$3.810 +0.26% 342,030
06/08/26 US$3.800 +1.06% 503,348
05/08/26 US$3.760 -2.08% 741,941
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.800USD
Average target price
5.750USD
Spread / Average Target
+51.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock